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Neurodegenerative diseases are important causes 
of disability and death, with prominent examples 
including Alzheimer’s disease, Parkinson’s disease 
(PD) and motor neuron disease. Although familial 
clustering of these illnesses was well known before 
the advent of modern molecular genetics, meaningful strides in 
identifying the origin of neurodegenerative diseases have really only 
begun to be made in the past two decades. All these disorders are 
characterised by a small percentage of affected patients whose disease 
is clearly the result of Mendelian inherited genetic illness, either 
recessive or dominant. In particular, dominant disease is exemplified 
in the case of Alzheimer’s disease by presenilin 2 mutations that 
arose in German immigrants from the Volga river region in the 17th 
century,[1] and in PD by mutations in the LRRK2 protein that are 
linked to a founder effect dating back to the 2nd century, probably 
in Ashkenazi Jews.[2]
Such autosomal dominant families enable a crucial aspect of 
neurodegenerative disease to be addressed, namely the identification 
of biomarkers that can serve to identify the earliest features of 
the onset of disease. These biomarkers range from proteins in 
cerebrospinal fluid, such as amyloid and tau, to magnetic resonance 
imaging scans of the brain volumes of cortex and temporal lobe 
structures, and positron emission tomography scans of markers of 
neurodegeneration, such as amyloid.[3,4]
It is clear, certainly in the case of Alzheimer’s disease, that by the 
time even mild memory impairment has developed there is wide­
spread pathological change that is highly likely to be irreversible.[5] 
Similarly, although tremor may the best­appreciated manifestation 
of dopaminergic cell loss in PD, it is clearly preceded by a slowly 
progressive process that gradually ascends up the brainstem and 
may produce features of brainstem dysfunction as long as 25 years 
before the onset of classic PD.[6,7] In general, it would probably 
be most useful to identify individuals who are genetically at risk 
for developing neurodegenerative illness, and monitor particular 
biomarkers, in the event that successful therapies become available.
After the initial euphoria when the first genes associated with 
Alzheimer’s disease and PD were identified, a major issue has been 
the extrapolation of these findings to the much more common 
situation of sporadic disease in individuals who lack a clear­cut 
family history. So far, although genome­wide association studies 
(GWASs) have shown much promise, they have failed to deliver 
many significant advances with regard to the genetic cause of 
neurodegenerative disease. In particular, the power of such studies 
has been limited, and not uncommonly GWASs have only served 
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to confirm genetic targets already identified by other methods.[8] 
It could be argued that a sporadic case is more likely to have an 
environmental cause, but the evidence for the environment playing 
an important role in the causation of neurodegenerative disease is 
not particularly strong.
A major advantage of genetic studies is not only that they 
identify the cause of illness, but also that they shed light on 
the various molecular pathways implicated in the causation of 
neurodegenerative disease.[9] This clearly has significant implications 
for the development of treatments that would potentially be of benefit 
for patients harbouring preclinical or manifest mutations, as well as 
for patients with sporadic disease.
To reiterate, the identification of mutations has profound 
implications for understanding the cause of disease, and it is likely 
that it will only be through the understanding of the mechanisms of 
cell injury and death in neurodegenerative disease that advances will 
be made in therapeutics.
One major issue regarding the utility of genetics when applied to 
neurodegenerative disease is that age is a major risk factor, and many 
patients may not develop illness simply because they die before the 
disease manifests. Confirmation of a family history of an illness being 
inherited in a particular pattern may therefore be difficult. Over and 
above mutation analysis, genealogical studies can be very useful in 
populations where there are common founder effects and church 
records. Such is the case for the original Dutch population that settled 
in the Cape from the mid­1600s, and with the admixture largely of 
German and French immigrants, ultimately developed into the South 
African (SA) Afrikaner population. As is well known, this population 
has well­established founder effects for a wide range of conditions, of 
which the best­known examples are familial hypercholesterolaemia 
and variegate porphyria. Furthermore, the Afrikaner population has 
genealogies that range from the 1600s through the early 1800s and 
later, and are well documented and recorded.[10]
Interestingly, with respect to neurodegenerative disease, there is 
some evidence for a founder effect for Huntington’s disease in SA, 
possibly arising from an early Dutch settler, since there is a common 
haplotype indicative of a European origin.[11,12] In the study by 
Geldenhuys et al.[13] published in this issue of the SAMJ, genealogies 
of 12 Afrikaner families were investigated in detail using the records 
of the Genealogical Institute of South Africa in Stellenbosch and 
other sources. The genealogical research concentrated on those 
with a family history suggestive of either dominant or recessive 
inheri tance of PD. The 12 families were shown to be linked to a 
single ancestral couple, and this finding was further supported by 
confirmation of ancestral lines to the putative founder couple in an 
additional 28 families, also of Afrikaner origin and with a history 
of PD. The affected family members had a mean age of onset of 
PD of only 52 years, which is considerably less than that in typical 
idiopathic disease and suggests a genetic origin for the illness.[14] The 
founder couple was of Dutch and German ancestry and married in 
the Cape in 1668.
This finding is of importance for two reasons. Firstly, given that 
established genetic causes of PD have not been identified in the 
Afrikaner population, it appears likely that this population carries 
unique mutations that remain to be identified by genome­wide 
screening.[15,16] Secondly, in the event that effective treatments are 
developed, particularly for presymptomatic patients, the Afrikaner 
population may be considered to be at risk and requiring careful 
assessment with accurate biomarkers.
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